The foundational understanding of how adhesion G-protein coupled receptors initiate cellular responses may need revision, with implications for developing therapies targeting brain development, wound healing, and cancer progression. These receptors have long been thought to require a precise molecular scissors mechanism to function properly.
New research demonstrates that the adhesion GPCR Adgrg1/Gpr56 can activate cellular signaling through two distinct pathways in mouse models. The traditional mechanism involves receptor self-cleavage that separates the protein into two fragments, releasing a tethered agonist to trigger downstream responses. However, investigators discovered the receptor also functions through cleavage-independent pathways that bypass this fragmentation process entirely. Mouse studies revealed tissue-specific preferences for each activation mode, with certain developmental processes relying primarily on the non-cleavage mechanism.
This dual-function discovery reshapes therapeutic strategies for conditions involving adhesion GPCRs, including neurological disorders and metastatic cancers. The cleavage-independent pathway may explain why some AGPCR-targeting drugs have shown inconsistent clinical results - they may have been designed around incomplete mechanistic models. The finding also suggests that AGPCR dysfunction in disease states could stem from disruptions in either pathway, requiring more nuanced diagnostic and treatment approaches. While this single-receptor study provides compelling evidence for alternative activation modes, the broader family of 33 human adhesion GPCRs likely exhibits similar mechanistic diversity. Future research must determine whether this dual functionality represents a universal AGPCR characteristic or receptor-specific adaptation, as this distinction will fundamentally influence drug development strategies targeting these therapeutically important but mechanistically complex proteins.